37 373

Cited 30 times in

Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B.

Authors
Lee, MH; Lee, da M; Kim, SS; Cheong, JY; Cho, SW
Citation
Journal of medical virology, 83(7):1178-1186, 2011
Journal Title
Journal of medical virology
ISSN
0146-66151096-9071
Abstract
Recent studies have suggested that quantifying the serum HBsAg levels can predict the response to pegylated interferon. We aimed to determine the change in serum HBsAg levels during entecavir (ETV) treatment and the correlation with treatment response in chronic HBeAg-positive and HBeAg-negative hepatitis B patients. Serial HBsAg levels were measured using the Architect assay (Abbott Laboratories, Abbott Park, IL) in sera from 101 treatment-naive chronic hepatitis B (CHB) patients receiving ETV. During treatment, in HBeAg-positive patients, the mean HBsAg level was 3.51, 3.22, 3.34, 3.36, and 3.40 log₁₀  IU/ml at baseline, 3, 6, 12, and 24 months, respectively, and there was no significant change compared with the baseline level, except the decline at 3 months (P = 0.009). In HBeAg-negative patients, the mean level of serum HBsAg showed increase with 3.06, 3.09, 3.20, 3.26, and 3.27 log₁₀  IU/ml at baseline, 3, 6, 12, and 24 months of treatment, respectively. In HBeAg-positive patients, HBV-DNA negativity (<2,000 copies/ml; P = 0.010) and HBsAg level < 3,000 IU/ml (P = 0.026) at 3 months were independent predictors of HBeAg loss/seroconversion at 12 months. After 24 months of treatment, the HBsAg levels at baseline (P = 0.046) was an independent factor of HBeAg loss/seroconversion. In HBeAg-negative patients, undetectable HBV DNA at 6 months was an independent factor predicting undetectable HBV DNA after 12 months of therapy. The level of serum HBsAg before and during therapy was a good predictor of HBeAg loss/seroconversion in naïve HBeAg-positive CHB patients receiving entecavir.
MeSH terms
AdultAlanine Transaminase/analysisAntiviral Agents/*administration & dosage/immunologyAspartate Aminotransferase, Cytoplasmic/analysisDNA, Viral/blood/immunologyFemaleGuanine/administration & dosage/*analogs & derivatives/immunologyHepatitis B Antibodies/blood/immunologyHepatitis B Surface Antigens/*blood/immunologyHepatitis B virus/immunologyHepatitis B, Chronic/*blood/*drug therapy/immunologyHumansLongitudinal StudiesMaleMiddle AgedPredictive Value of TestsTreatment OutcomeViral Load
DOI
10.1002/jmv.22089
PMID
21567421
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Gastroenterology
AJOU Authors
이, 명희김, 순선정, 재연조, 성원
Files in This Item:
1178-1186.pdfDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse